NewsRoom

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014

201320122011201020092008

Nov 10, 2020
MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights
--Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
Nov 9, 2020
MEI Pharma to Present at Two Upcoming Investor Healthcare Conferences
Oct 2, 2020
Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma
Sep 15, 2020
MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing
Sep 9, 2020
MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights
- Strong cash position of ~$183 million at start of fiscal year 2021 -
Sep 4, 2020
MEI Pharma to Present at Upcoming Investor Conferences in September
Sep 2, 2020
MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020
Aug 4, 2020
MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020
Jul 2, 2020
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
May 27, 2020
MEI Pharma to Present at the Jefferies Virtual Healthcare Conference
May 26, 2020
MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program
- Event scheduled for June 2, 2020 at 8am ET; featuring leading KOL Matthew Matasar, M.D. -
May 14, 2020
MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress
May 13, 2020
Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
- Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT -
May 13, 2020
MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Onc
- 83% overall response rate in patients with relapsed or refractory follicular lymphoma -
May 7, 2020
MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights
-- ME-401 global alliance with Kyowa Kirin executed, $100M in upfront payment and MEI eligible to receive up to an additional $582.5M in milestones --